{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:04:36Z","timestamp":1792231476441,"version":"4.4.0"},"reference-count":127,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2015,12,2]]},"DOI":"10.1517\/17460441.2015.1094051","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T02:21:54Z","timestamp":1447381314000},"page":"1363-1377","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":60,"title":["The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C"],"prefix":"10.1517","volume":"10","author":[{"given":"Ivan","family":"Gentile","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Enrico","family":"Maraolo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Borgia","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62401-6"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01934.x"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"issue":"1","key":"e_1_3_2_6_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower E","year":"2014","unstructured":"Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):30","journal-title":"J Hepatol"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.8352"},{"key":"e_1_3_2_9_1","first-page":"399","article-title":"Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection","volume":"29","author":"Gentile I","year":"2015","unstructured":"Gentile I, Scarano F, Celotti A, et al.Low Vitamin D. Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection. In Vivo 2015;29:399-404","journal-title":"In Vivo"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.850073"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i10.1377"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002656"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00319.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.09.013"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3046"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70127-1"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.929497"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.921680"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.892581"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"e_1_3_2_26_1","first-page":"00208","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"21","author":"EASL","year":"2015","unstructured":"EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;21:00208-1","journal-title":"J Hepatol"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i18.2793"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.023"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12601"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.283"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-007-0259-1"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.05.014"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22070"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ197"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903501505"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12342"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2014.970123"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.11.005"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990178"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000360830"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02411.x"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00329.x"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.795543"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(00)80031-3"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13034"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80401-0"},{"key":"e_1_3_2_51_1","first-page":"289","article-title":"Hepatitis C virus-specific directly acting antiviral drugs","volume":"369","author":"Delang L","year":"2013","unstructured":"Delang L, Neyts J, Vliegen I, et al. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013;369:289-320","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.10"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0179-7"},{"key":"e_1_3_2_54_1","unstructured":"Gounder C. A better treatment for hepatitis C. The New Yorker December 2013. Available from: www.newyorker.com\/tech\/elements\/a-better-treatment-for-hepatitis-c [Last accessed 31 August 2013]"},{"key":"e_1_3_2_55_1","unstructured":"Pharmasset Ltd. Modified fluorinated nucleoside analogues. WO2005003147A2; 2005"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo901345j"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja502205q"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_3_2_60_1","first-page":"31","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"31","author":"Kirby BJ","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015;31:31","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016212804288"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.855126"},{"key":"e_1_3_2_64_1","unstructured":"Babusis D Curry MP Denning J et al. Translational Studies to understand the mechanism of liver delivery by sofosbuvir. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington DC USA 2014"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-10"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2733"},{"key":"e_1_3_2_67_1","unstructured":"Hebner CM Lee YJ Han B et al. In vitro pangenotypic and combination activity of sofosbuvir in stable replicon cell lines. Presented at 63th Annual Meeting of the American Association for the Study of Liver Diseases; Boston MA USA 2012"},{"key":"e_1_3_2_68_1","first-page":"331","article-title":"Sofosbuvir: a novel oral agent for chronic hepatitis C","volume":"27","author":"Cholongitas E","year":"2014","unstructured":"Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014;27:331-7","journal-title":"Ann Gastroenterol"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","unstructured":"Lawitz E Rodriguez-Torres M Cornpropst MT et al. The effect of hepatic impairment in the pharmacokinetics and antiviral activity of PSI- 7977 in hepatitis C infected subjects treated for several days. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona Spain; 2012","DOI":"10.1016\/S0168-8278(12)61142-8"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","unstructured":"Cornpropst M Denning J Clemons D et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona Spain; 2012","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"e_1_3_2_71_1","unstructured":"Gane E Robson RA Bonacini M et al. Safety antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston MA; 2014"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01262-12"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-12"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S65255"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.018"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_3_2_82_1","first-page":"31","article-title":"Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies","volume":"15","author":"Mangia A","year":"2014","unstructured":"Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Dig Liver Dis 2014;15:31","journal-title":"Dig Liver Dis"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-12"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27375"},{"key":"e_1_3_2_87_1","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/S0168-8278(14)61331-3","article-title":"Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase III studies","volume":"60","author":"Gordon S","year":"2014","unstructured":"Gordon S, Contai S, Tournee W. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase III studies. J Hepatol 2014;60:S361-522","journal-title":"J Hepatol"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13515825"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S52629"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27890"},{"key":"e_1_3_2_95_1","first-page":"321","article-title":"All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial","volume":"60","author":"Kapoor R","year":"2014","unstructured":"Kapoor R, Kohli A, Sidharthan S. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014;60:321","journal-title":"Hepatology"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v4.i1.1"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"e_1_3_2_100_1","article-title":"HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It\u2019s Time to End Segregation and Integrate HIV Patients Into HCV Trials","volume":"9","author":"Shafran SD","year":"2015","unstructured":"Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It\u2019s Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;9. [Epub ahead of print]","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_101_1","unstructured":"Naggie S Cooper C Saag M et al. Ledipasvir\/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV. Presented at Conference on Retroviruses and Opportunistic Infections (CROI); Seattle WA USA; 2015"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31773"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32418"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"e_1_3_2_107_1","first-page":"00682","article-title":"Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease","volume":"15","author":"Charlton M","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015;15:00682-4","journal-title":"Gastroenterology"},{"key":"e_1_3_2_108_1","unstructured":"Recommendations for Testing Managing and Treating Hepatitis C. Guidelines from AASLD\/IDSA\/IAS\u2013USA. Available from: www.HCVguidelines.org [Last accessed 31 August 2015]"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"e_1_3_2_110_1","first-page":"58","article-title":"In brief: severe bradycardia with sofosbuvir and amiodarone","volume":"57","year":"2015","unstructured":"In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther 2015;57:58","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_2_111_1","first-page":"219","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort act)","volume":"60","author":"Jensen DM","year":"2014","unstructured":"Jensen DM, O\u2019Leary JG, Pockros PJ. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort act). Hepatology 2014;60:219","journal-title":"Hepatology"},{"key":"e_1_3_2_112_1","first-page":"220","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich D","year":"2014","unstructured":"Dieterich D, Bacon BR, Flamm SL. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60:220","journal-title":"Hepatology"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.02.002"},{"issue":"1","key":"e_1_3_2_114_1","doi-asserted-by":"crossref","first-page":"006","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky JM","year":"2015","unstructured":"Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62(1 Suppl):006","journal-title":"J Hepatol"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02283.x"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1985-7"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20210"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S44375"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2055"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126984"},{"key":"e_1_3_2_123_1","first-page":"11","article-title":"Chronic hepatitis C: treat everyone now or stratify by disease?","volume":"61","author":"Reiberger T","year":"2015","unstructured":"Reiberger T. Chronic hepatitis C: treat everyone now or stratify by disease? Minerva Gastroenterol Dietol 2015;61:11-19","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.972364"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"e_1_3_2_126_1","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection","author":"Foster GR","year":"2015","unstructured":"Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection. Gastroenterology 2015; Epub ahead of print","journal-title":"Gastroenterology"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_3_2_128_1","unstructured":"Esmat GE Shiha G Omar RF et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston (MA) USA; 2014"},{"key":"e_1_3_2_129_1","unstructured":"Gane EJ Hyland RH An D et al. High efficacy of LDV\/SOF regimens for 12 weeks with HCV genotype 3 or 6 infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston MA USA; 2014"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17460441.2015.1094051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:55:22Z","timestamp":1770922522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17460441.2015.1094051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":127,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12,2]]}},"alternative-id":["10.1517\/17460441.2015.1094051"],"URL":"https:\/\/doi.org\/10.1517\/17460441.2015.1094051","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}